Spectrum Management Group LLC Sells 1,374 Shares of Johnson & Johnson (NYSE:JNJ)

Spectrum Management Group LLC lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 87.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 196 shares of the company’s stock after selling 1,374 shares during the quarter. Spectrum Management Group LLC’s holdings in Johnson & Johnson were worth $26,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Tamarack Advisers LP bought a new stake in shares of Johnson & Johnson during the 4th quarter worth about $18,035,000. Orser Capital Management LLC lifted its position in shares of Johnson & Johnson by 44.2% during the 4th quarter. Orser Capital Management LLC now owns 1,875 shares of the company’s stock worth $272,000 after purchasing an additional 575 shares during the last quarter. S.E.E.D. Planning Group LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth about $387,000. Bay Rivers Group acquired a new position in shares of Johnson & Johnson during the 4th quarter worth about $339,000. Finally, Duff & Phelps Investment Management Co. lifted its position in shares of Johnson & Johnson by 1.4% during the 4th quarter. Duff & Phelps Investment Management Co. now owns 29,455 shares of the company’s stock worth $4,297,000 after purchasing an additional 400 shares during the last quarter. Institutional investors own 68.45% of the company’s stock.

Several equities analysts recently weighed in on JNJ shares. Raymond James boosted their price objective on Johnson & Johnson from $153.00 to $157.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 15th. Stifel Nicolaus boosted their price objective on Johnson & Johnson from $140.00 to $155.00 and gave the stock a “hold” rating in a research report on Wednesday, April 15th. Barclays boosted their price objective on Johnson & Johnson from $173.00 to $182.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 29th. Argus reissued a “buy” rating and set a $155.00 price objective (down previously from $165.00) on shares of Johnson & Johnson in a research report on Friday, March 27th. Finally, Citigroup upped their price target on Johnson & Johnson from $150.00 to $165.00 and gave the company a “buy” rating in a report on Wednesday, April 15th. Four investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $163.47.

Shares of JNJ opened at $144.56 on Wednesday. The stock has a market cap of $380.36 billion, a PE ratio of 19.12, a PEG ratio of 3.14 and a beta of 0.71. Johnson & Johnson has a 1 year low of $109.16 and a 1 year high of $157.00. The stock has a 50 day simple moving average of $147.76 and a 200-day simple moving average of $142.57. The company has a current ratio of 1.31, a quick ratio of 1.05 and a debt-to-equity ratio of 0.41.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 14th. The company reported $2.30 EPS for the quarter, topping the Zacks’ consensus estimate of $2.03 by $0.27. The business had revenue of $20.69 billion for the quarter, compared to analyst estimates of $19.48 billion. Johnson & Johnson had a return on equity of 39.71% and a net margin of 24.47%. Johnson & Johnson’s revenue for the quarter was up 3.3% on a year-over-year basis. During the same period in the prior year, the company earned $2.10 EPS. On average, sell-side analysts forecast that Johnson & Johnson will post 7.68 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be given a dividend of $1.01 per share. The ex-dividend date is Friday, May 22nd. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.95. This represents a $4.04 dividend on an annualized basis and a yield of 2.79%. Johnson & Johnson’s dividend payout ratio is 46.54%.

In other Johnson & Johnson news, Director William D. Perez purchased 500 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The shares were acquired at an average cost of $127.69 per share, for a total transaction of $63,845.00. Following the transaction, the director now directly owns 16,030 shares in the company, valued at $2,046,870.70. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.27% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: Compound Interest and Why It Matters When Investing

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).